Literature DB >> 3160379

Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative.

J C van Gemert, M C Berenbaum, G H Gijsbers.   

Abstract

Red light (c. 630 nm) is almost universally used in tumour phototherapy as it is the most penetrating of the porphyrin excitation wavebands. However, measurements of tumour attenuation of light of different wavelengths and of the excitation spectrum of haematoporphyrin derivative in vitro suggested that green light might be more efficient than red in destroying thin tumours. Experimentally, we confirmed this for tumours up to approximately 1.2 mm thick, a depth exceeding that of most carcinomas-in-situ. The superiority of green light over red in terms of the illumination time required to produce equivalent depths of necrosis may extend to greater depths (3-4 mm) if the former is produced by an argon laser and the latter by an argon-pumped dye laser. The relation between depth of necrosis Zn and light dose D is shown to be Zn = sigma gamma-1 1n(D/theta gamma) where sigma gamma is the attenuation coefficient for light at wavelength gamma and theta gamma the threshold light dose for producing necrosis at that wavelength. This logarithmic relationship suggests that it may be difficult to eradicate large tumours merely by increasing the light dose, and indicates the need for other approaches.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160379      PMCID: PMC1977172          DOI: 10.1038/bjc.1985.146

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Measurements on the depth of penetration of light (0.35--1.0 microgram) in tissue.

Authors:  J Eichler; J Knof; H Lenz
Journal:  Radiat Environ Biophys       Date:  1977-10-12       Impact factor: 1.925

2.  Sensitivity improvements in spectrophospho-fluorimetry.

Authors:  J Langelaar; G A de Vries; D Bebelaar
Journal:  J Sci Instrum       Date:  1969-02

3.  The optics of human skin.

Authors:  R R Anderson; J A Parrish
Journal:  J Invest Dermatol       Date:  1981-07       Impact factor: 8.551

4.  Quantitative evaluation of the radiosensitivity of cells of a transplantable rhabdomyosarcoma in the rat.

Authors:  H S Reinhold
Journal:  Eur J Cancer       Date:  1966-02       Impact factor: 9.162

5.  A model approach to laser coagulation of dermal vascular lesions.

Authors:  M J van Gemert; J P Henning
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

6.  Energetics and efficiency of photoinactivation of murine tumor cells containing hematoporphyrin.

Authors:  T J Dougherty; C J Gomer; K R Weishaupt
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

7.  Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy.

Authors:  R C Benson; J H Kinsey; D A Cortese; G M Farrow; D C Utz
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

8.  Hematoporphyrin derivative and laser photoradiation in the diagnosis and treatment of bladder cancer.

Authors:  A Tsuchiya; N Obara; M Miwa; T Ohi; H Kato; Y Hayata
Journal:  J Urol       Date:  1983-07       Impact factor: 7.450

9.  In vivo biological activity of the components of haematoporphyrin derivative.

Authors:  M C Berenbaum; R Bonnett; P A Scourides
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  9 in total
  8 in total

Review 1.  Current concepts in gastrointestinal photodynamic therapy.

Authors:  J Webber; M Herman; D Kessel; D Fromm
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

2.  The photodynamic effect of a pulsed dye laser on human bladder carcinoma cells in vitro.

Authors:  A J Pope; J R Masters; A J MacRobert
Journal:  Urol Res       Date:  1990

3.  CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy.

Authors:  Michael Jermyn; Scott C Davis; Hamid Dehghani; Matthew T Huggett; Tayyaba Hasan; Stephen P Pereira; Stephen G Bown; Brian W Pogue
Journal:  Phys Med Biol       Date:  2014-03-20       Impact factor: 3.609

Review 4.  Current status of photodynamic therapy in oncology.

Authors:  R van Hillegersberg; W J Kort; J H Wilson
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

5.  Lipofuscin-associated photo-oxidative stress during fundus autofluorescence imaging.

Authors:  Michel M Teussink; Stanley Lambertus; Frits F de Mul; Malgorzata B Rozanowska; Carel B Hoyng; B Jeroen Klevering; Thomas Theelen
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

6.  Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II.

Authors:  P Grosjean; G Wagnieres; C Fontolliet; H van den Bergh; P Monnier
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light.

Authors:  T H Foster; S L Gibson; R F Raubertas
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

8.  Optimization of singlet oxygen production from photosensitizer-incorporated, medically relevant hydrogels.

Authors:  Áine T De Baróid; Colin P McCoy; Rebecca A Craig; Louise Carson; Gavin P Andrews; David S Jones; Sean P Gorman
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2015-10-27       Impact factor: 3.368

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.